https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49803 38 years (1.34; 1.04–1.73); those with disease duration > 7 years (1.33; 1.01–1.74); those with EDSS score < 6 (1.21; 1.01–1.46) and ≥ 6 (1.93; 1.11–3.34); and patients with no new MRI lesion (1.73; 1.19–2.51). Conclusions: Overall, in women, younger patients, those with shorter disease durations, and patients with pre-treatment relapses, natalizumab was associated with a lower frequency of multiple sclerosis relapses than fingolimod. It was also associated with an increased chance of recovery from disability among most patients, particularly women and those with no recent MRI activity.]]> Wed 31 May 2023 15:59:42 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36042 Wed 29 Jan 2020 16:35:27 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38068 p <0.001), longer disease duration (HR=1.01, p=0.038), a higher Expanded Disability Status Scale score (HR=1.30, p<0.001), more rapid disability trajectory (HR=2.82, p<0.001) and greater number of relapses in the previous year (HR=1.07, p=0.010) were independently associated with an increased risk of secondary progressive multiple sclerosis. Improving disability (HR=0.62, p=0.039) and disease-modifying therapy exposure (HR=0.71, p=0.007) were associated with a lower risk. Recent cerebral magnetic resonance imaging activity, evidence of spinal cord lesions and oligoclonal bands in the cerebrospinal fluid were not associated with the risk of conversion. Conclusion:Risk of secondary progressive multiple sclerosis increases with age, duration of illness and worsening disability and decreases with improving disability. Therapy may delay the onset of secondary progression.]]> Wed 24 May 2023 12:22:34 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33927 Wed 23 Jan 2019 15:30:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22648 Wed 22 May 2019 14:50:34 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51652 Wed 13 Sep 2023 10:00:03 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13691 Wed 11 Apr 2018 17:01:07 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28397 Wed 11 Apr 2018 15:14:13 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25641 Wed 11 Apr 2018 15:12:45 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13693 Wed 11 Apr 2018 14:32:54 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28923 Wed 11 Apr 2018 10:33:05 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54611 Wed 06 Mar 2024 10:38:32 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51272 Tue 29 Aug 2023 15:42:42 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34542 Tue 26 Mar 2019 15:11:01 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39111 Tue 21 Mar 2023 17:45:24 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27384 Tue 13 Oct 2020 19:16:32 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27446 Tue 13 Oct 2020 19:11:18 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49895 Tue 13 Jun 2023 15:49:48 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51624 Tue 12 Sep 2023 14:37:58 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51450 Tue 05 Sep 2023 17:56:18 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53990 Thu 25 Jan 2024 13:04:15 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52212 88% likely to be sustained (events with score ˃1.5). Conclusions: Clinicodemographic characteristics of 6-month confirmed disability progression events identify those at high risk of sustained long-term disability. This knowledge will allow future trials to better assess the effect of therapy on long-term disability accrual.]]> Thu 05 Oct 2023 10:22:58 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33303 Thu 04 Oct 2018 16:49:43 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36736 Thu 02 Jul 2020 16:31:45 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41240 Sat 30 Jul 2022 12:19:30 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20798 Sat 24 Mar 2018 08:05:59 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17471 Sat 24 Mar 2018 08:04:07 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19533 95% of the identified indication bias. Slightly lower relapse incidence was found among patients treated with glatiramer acetate or subcutaneous interferon β-1a relative to intramuscular interferon β-1a and interferon β-1b (p≤0.001). No differences in 12-month confirmed progression of disability were observed. Conclusion: Small but statistically significant differences in relapse outcomes exist among the injectable immunomodulators. MSBase is sufficiently powered to identify these differences and reflects practice in tertiary MS centres. While the present study controlled indication, selection and attrition bias, centre-dependent variance in data quality was likely.]]> Sat 24 Mar 2018 08:02:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19821 Sat 24 Mar 2018 07:56:56 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20329 Sat 24 Mar 2018 07:55:11 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28472 2 than ≤2. Two-point progression was uncommon for EDSS score of <2 and more common at EDSS score of 4. Conclusions: EDSS rank stability increases with disease duration, probably due to reduced relapses and less random variation in later disease. After 4 years duration, EDSS rank was highly predictive of EDSS rank 5 years later. Risk of progression by 10 years was highly dependent on EDSS score at 5 years duration. We confirm the utility of EDSS ranking to predict 5-year outcome in individuals 4 years after disease onset.]]> Sat 24 Mar 2018 07:39:35 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28467 Sat 24 Mar 2018 07:39:33 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28805 P < 10⁻¹²). However, the female-to-male ratio in patients with relapse-onset multiple sclerosis and zero relapses in any given year was double that of the patients with primary progressive multiple sclerosis. Patient age was a more important determinant of decline in relapse incidence than disease duration (P < 10⁻¹²). Females are predisposed to higher relapse activity than males. However, this difference does not explain the markedly lower female-to-male sex ratio in primary progressive multiple sclerosis. Decline in relapse activity over time is more closely related to patient age than disease duration.]]> Sat 24 Mar 2018 07:38:27 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30101 Sat 24 Mar 2018 07:37:59 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30262 p [signed-rank] < 0.0001), a 64% reduction in the rate of first relapse (hazard ratio [HR] 0.36, 95% confidence interval [CI] 0.28–0.47; p < 0.001), and a 27% reduction in the rate of discontinuation (HR 0.73, 95% CI 0.58–0.93; p = 0.01), compared with first-line IFN-β/GA therapy. Confirmed disability progression and area under the Expanded Disability Status Scale–time curve analyses were not significant. Similar relapse and treatment persistence results were observed in each of the higher disease activity subgroups. Conclusions: This study provides Class IV evidence that first-line natalizumab for RRMS improves relapse and treatment persistence outcomes compared to first-line IFN-β/GA. This needs to be balanced against the risk of progressive multifocal leukoencephalopathy in natalizumab-treated patients. Classification of evidence: This study provides Class IV evidence that first-line natalizumab for RRMS improves relapse rates and treatment persistence outcomes compared to first-line IFN-β/GA.]]> Sat 24 Mar 2018 07:33:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29942 -23). A reciprocal relationship was seen for ambient ultraviolet radiation (UVR), with a significantly increasing AAO for patients with MS per each quartile increment of ambient UVR (p=1.56×10^-17). We found that the AAO of female patients was ~5 months earlier than male patients (p=0.002). AAO of progressive-onset patients with MS were ~9 years later than relapsing-onset patients (p=1.40×10^-265). Conclusions: An earlier AAO in higher latitude regions was found in this worldwide European-descent cohort and correlated inversely with variation in latitudinal UVR. These results suggest that environmental factors which act at the population level may significantly influence disease severity characteristics in genetically susceptible populations.]]> Sat 24 Mar 2018 07:31:01 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23959 Sat 24 Mar 2018 07:10:07 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49695 Mon 29 May 2023 12:46:42 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37732 p = 0.001), brainstem onset (HR = 0.45, p = 0.009), azathioprine (HR = 0.46, p <0.001) and mycophenolate mofetil (HR = 0.09, p = 0.012) were associated with a reduced risk of relapse. A greater EDSS was associated with age (β = 0.45 (per decade), p<0.001) and disease duration (β = 0.07 per year, p <0.001). A slower increase in EDSS was associated with azathioprine (β = -0.48, p <0.001), mycophenolate mofetil (β = -0.69, p = 0.04) and rituximab (β = -0.35, p = 0.024). Interpretation: This study has demonstrated that azathioprine and mycophenolate mofetil reduce the risk of relapses and disability progression is modified by azathioprine, mycophenolate mofetil and rituximab. Age and disease duration were the only patient characteristics that modified the risk of relapse and disability in our cohort.]]> Mon 29 Mar 2021 13:09:59 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48108 Mon 27 Feb 2023 15:18:00 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36719 Mon 24 Aug 2020 10:45:35 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41847 p = 0.010); but no differences in spontaneous abortions, term or preterm births. Conclusions: We report low pregnancy incidence rates, with increasing number of pregnancies conceived on DMT over the past 12-years. The median duration of DMT exposure in pregnancy was relatively short at one month.]]> Mon 15 Aug 2022 10:27:59 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25306 Mon 06 Mar 2023 17:55:37 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41309 Mon 01 Aug 2022 12:30:36 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46553 Fri 25 Nov 2022 11:33:34 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51685 Fri 15 Sep 2023 09:36:29 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34630 Fri 05 Apr 2019 11:37:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51340 Fri 01 Sep 2023 13:35:50 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34026 80%) for relapse incidence during the first year and for disability outcomes, moderate for relapse incidence in Years 2–4 and for the change in the cumulative disease burden, and low for conversion to secondary progressive disease and treatment discontinuation. External validation showed similar results, demonstrating high external validity for disability and relapse outcomes, moderate external validity for cumulative disease burden and low external validity for conversion to secondary progressive disease and treatment discontinuation. We conclude that demographic, clinical and paraclinical information helps predict individual response to disease-modifying therapies at the time of their commencement.]]> Fri 01 Feb 2019 10:45:46 AEDT ]]>